Drug therapy of leprosy

Cover Page


Cite item

Full Text

Abstract

Leprosy (Hansen’s disease) is a chronic granulomatous bacterial infection mainly affecting the skin and peripheral nervous system yet also involving other organs and systems as a result of a pathological process. The causative agent of leprosy - Mycobacterium leprae - is an obligate intracellular microorganism. Despite the removal of a threat of a leprosy epidemic, European countries still record outbreaks of the disease mainly among migrants coming from endemic areas. A golden standard of the treatment of leprosy is a WHO-recommended combined drug therapy comprising drugs such as dapsone, clofazimine and rifampicin. The article provides current data on the mechanisms of action, efficacy and safety of these drugs and their combined scheme of treatment obtained as a result of clinical trials. Moreover, it also reviews new regimens of the drug therapy of leprosy including those with the use of drugs from the group of fluoroquinols as well as immunotherapy of the disease.

About the authors

A. A. Kubanov

ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России; ГБОУ ДПО «Российская медицинская академия последипломного образования» Минздрава России

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

A. E. Karamova

ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России

Email: karamova@cnikvi.ru
Russian Federation

A. A. Vorontsova

ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России

Email: noemail@neicon.ru
Russian Federation

P. A. Kalinina

ГБОУ ДПО «Российская медицинская академия последипломного образования» Минздрава России

Email: noemail@neicon.ru
Russian Federation

References

  1. Bret S. et al. [Epidemiological survey of leprosy conducted in metropolitan France between 2009 and 2010]. Ann Dermatol Venereol 2013; 140: 347-352.
  2. Campbell E. a. E.A. et al. Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell 2001; 104: 901-12.
  3. Cholo M.C. et al. Clofazimine: current status and future prospects. J Antimicrob Chemother 2012; 67: 290-298.
  4. Cunha S.S. et al. BCG revaccination does not protect against leprosy in the Brazilian Amazon: A cluster randomised trial. PLoS Negl Trop Dis 2008; 2.
  5. Desai A.C., Bhide M.B. Hydnocarpus oil as an antileprotic agent in footpad technique. Lepr India 1977; 49: 360-363.
  6. Dessinioti C., Katsambas A.D. Leprosy (Hansen’s disease). European Handbook of Dermatological Treatments Third Edition 2015; 513-519.
  7. Gelber R.H., Grosset J. The chemotherapy of leprosy: an interpretive history. Lepr Rev 2012; 83: 3: 221-40.
  8. Gupta R., Kar H.K., Bharadwaj M. Revalidation of various clinical criteria for the classification of leprosy - a clinic-pathological study. Lepr Rev 2012; 83: 354-362.
  9. Ishii N. et al. [Report of the tenth meeting of the WHO Technical Advisory Group on Leprosy Control]. Nihon Hansenbyo Gakkai Zasshi 2010; 79: 37-42.
  10. Ji B., Grosset J. Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. Lepr Rev 2000; 71 Suppl: S81-S87.
  11. Kar H.K., Gupta R. Treatment of leprosy. Clin Dermatol 2015; 33: 55-65.
  12. Katoch K. et al. Chemotherapy trials in MB leprosy using conventional and newer drugs pefloxacin and minocycline. Indian J Dermatol Venereol Leprol 2000; 66: № 1: 18-25.
  13. Kroger A. et al. International open trial of uniform multi-drug therapy regimen for 6 months for all types of leprosy patients: Rationale, design and preliminary results. Trop Med Int Heal 2008; 13: 594-602.
  14. Malathi M., Thappa D.M. Fixed-duration therapy in leprosy: limitations and opportunities. Indian J Dermatol 2013; 58: 93-100.
  15. Massone C. et al. Imported leprosy in Italy. J Eur Acad Dermatology Venereol 2012; 26: 999-1006.
  16. Merle C.S.C., Cunha S.S., Rodrigues L.C. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev Vaccines 2010; 9: 209-22.
  17. Noordeen S.K. History of chemotherapy of leprosy. Clin Dermatol 2016; 34: 32-36.
  18. Pattyn S., Grillone S. Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy. Lepr Rev 2002; 73: 245-247.
  19. Prasad P.V. et al. MDT-MB therapy in pauci-bacillary leprosy: a clinicopathological assessment. Indian J Dermatol Venereol Leprol 2005; 71: 242-245.
  20. Ramos J., Romero D., Belinchon I. Epidemiology of Leprosy in Spain: The Role of the International Migration. PLoS Negl Trop Dis 2016; 10.
  21. Rao P.N., Suneetha S., Pratap D.V.S. Comparative study of uniform-MDT and WHO mDt in Pauci and Multi bacillary leprosy patients over 24 months of observation. Lepr Rev 2009; 80: 143-55.
  22. Rawat K.D. et al. Expression of CXCL10 (IP-10) and CXCL11 (I-TAC) chemokines during Mycobacterium tuberculosis infection and immunoprophylaxis with Mycobacterium indicus pranii (Mw) in guinea pig. Infect Genet Evol 2013; 13: 11-17.
  23. Ren Y.R. et al. Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS One 2008; 3.
  24. Sharma P. et al. Reactional states and neuritis in multibacillary leprosy patients following MDT with/ without immunotherapy with Mycobacterium w antileprosy vaccine. Lepr Rev 2000; 71: 193-205.
  25. Singh H. et al. Adverse effects of multi-drug therapy in leprosy, a two years’ experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur). Lepr Rev 2011; 82: 17-24.
  26. Taylor P.M., Alexander R. Clofazimine in the treatment of dapsone resistant leprosy. Lepr India 1976; 48: 709-712.
  27. Tejasvi T. et al. Evaluation of a new fixed duration (12 weeks) multi-drug regimen of bactericidal drugs in multibacillary leprosy. Indian J Lepr 2006; 78: 329-337.
  28. WHO. Global leprosy update, 2013: reducing disease burden. Relev. épidémiologique Hebd. Sect. d’hygiène du Secrétariat la Société des Nations = Wkly. Epidemiol Rec Heal Sect Secr Leag Nations 2014; 89: 36: 389-400.
  29. Mesnyankina O.A., Duyko V.V. Kachestvo zhizni i osobennosti vedeniya bolnyih leproy. Rossiyskiy zhurnal kozhnyih i venericheskih bolezney 2013; 2. [Меснянкина О.А., Дуйко В.В. Качество жизни и особенности ведения больных лепрой. Российский журнал кожных и венерических болезней 2013; 2.]
  30. WHO Methods for treatment. Leprosy: new drug regimens. WHO 2010; http://www.who.int/tdr/ research/progress/9900/meth.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Kubanov A.A., Karamova A.E., Vorontsova A.A., Kalinina P.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies